|
Video: What is a Stock Split?
|
|
uniQure is engaged in the field of gene therapy, focusing to develop single treatments for patients suffering from genetic and other diseases. Co. is developing etranacogene dezaparvovec, a gene therapy for patients with hemophilia B that is designed to restore Factor IX (FIX) activity, a protein for blood clotting. Etranacogene dezaparvovec includes an adeno-associated virus (AAV) 5 vector incorporating the FIX-Padua variant. Co. is also developing AMT-180 for hemophilia A, AMT-190 for fabry disease, and AMT-130 for huntington's disease. Co.'s AMT-150 is a one-time, intrathecally-administered, AAV gene therapy incorporating Co.'s miQURE silencing technology. According to our uniQure N.V. stock split history records, uniQure N.V. has had 0 splits. | |
|
uniQure N.V. (QURE) has 0 splits in our uniQure N.V. stock split history database.
Looking at the uniQure N.V. stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into uniQure N.V. shares, starting with a $10,000 purchase of QURE, presented on a split-history-adjusted basis factoring in the complete uniQure N.V. stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/25/2014 |
|
End date: |
04/23/2024 |
|
Start price/share: |
$11.00 |
|
End price/share: |
$4.75 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-56.82% |
|
Average Annual Total Return: |
-8.05% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$4,319.34 |
|
Years: |
10.00 |
|
|
|
|
|